Ahmed, F. K., B. E. Clark, D. R. Burton and R. Pantophlet (2012). "An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site." Vaccine 30(5): 922-930.

               

Andersson, K. M., E. Vardas, L. M. Niccolai, R. M. Van Niekerk, M. M. Mogale, I. M. Holdsworth, M. Bogoshi, J. A. McIntyre and G. E. Gray (2012). "Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township." Int J STD AIDS 23(10): 736-741.

               

Azoitei, M. L., Y. E. Ban, J. P. Julien, S. Bryson, A. Schroeter, O. Kalyuzhniy, J. R. Porter, Y. Adachi, D. Baker, E. F. Pai and W. R. Schief (2012). "Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope." J Mol Biol 415(1): 175-192.

               

Baeten, J., D. Donnell, P. Ndase, N. Mugo, J. Campbell, J. Wangisi, J. Tappero, E. Bukusi, C. Cohen, E. Katabira, A. Ronald, E. Tumwesigye, E. Were, K. Fife, J. Kiarie, C. Farquhar, G. John-Stewart, A. Kakia, J. Odoyo, A. Mucunguzi, E. Nakku-Joloba, R. Twesigye, K. Ngure, C. Apaka, H. Tamooh, F. Gabona, A. Mujugira, D. Panteleeff, K. Thomas and L. Kidoguchi (2012). "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women." N Engl J Med 367: 399 - 410.

               

Baruah, K., T. A. Bowden, B. A. Krishna, R. A. Dwek, M. Crispin and C. N. Scanlan (2012). "Selective deactivation of serum IgG: a general strategy for the enhancement of monoclonal antibody receptor interactions." J Mol Biol 420(1-2): 1-7.

Burton, D. R., R. Ahmed, D. H. Barouch, S. T. Butera, S. Crotty, A. Godzik, D. E. Kaufmann, M. J. McElrath, M. C. Nussenzweig, B. Pulendran, C. N. Scanlan, W. R. Schief, G. Silvestri, H. Streeck, B. D. Walker, L. M. Walker, A. B. Ward, I. A. Wilson and R. Wyatt (2012). "A Blueprint for HIV Vaccine Discovery." Cell Host Microbe 12(4): 396-407.

               

Burton, D. R., P. Poignard, R. L. Stanfield and I. A. Wilson (2012). "Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses." Science 337(6091): 183-186.

               

Champiat, S., R. A. Raposo, N. J. Maness, J. L. Lehman, S. E. Purtell, A. M. Hasenkrug, J. C. Miller, H. Dean, W. C. Koff, M. A. Hong, J. N. Martin, S. G. Deeks, G. E. Spotts, C. D. Pilcher, F. M. Hecht, E. G. Kallas, K. E. Garrison and D. F. Nixon (2012). "Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection." PLoS ONE 7(6): e39311.

               

Clark, B. E., K. Auyeung, E. Fregolino, M. Parrilli, R. Lanzetta, C. De Castro and R. Pantophlet (2012). "A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design." Chem Biol 19(2): 254-263.

               

Clarke, J. and W. Schief (2012). "Learning from Nature to design new biomolecules." Curr Opin Struct Biol 22(4): 395-396.

               

               

Cohen, M., M. McCauley and T. Gamble (2012). "HIV treatment as prevention and HPTN 052." Curr Opin HIV AIDS 7: 99 - 105.

               

Depetris, R. S., J. P. Julien, R. Khayat, J. H. Lee, R. Pejchal, U. Katpally, N. Cocco, M. Kachare, E. Massi, K. B. David, A. Cupo, A. J. Marozsan, W. C. Olson, A. B. Ward, I. A. Wilson, R. W. Sanders and J. P. Moore (2012). "Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers." J Biol Chem 287(29): 24239-24254.

               

Donaldson, M. M., S. F. Kao, L. Eslamizar, C. Gee, G. Koopman, M. Lifton, J. E. Schmitz, A. W. Sylwester, A. Wilson, N. Hawkins, S. G. Self, M. Roederer and K. E. Foulds (2012). "Optimization and qualification of an 8-color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre-clinical vaccine studies." J Immunol Methods 386(1-2): 10-21.

               

Doria-Rose, N. A., I. Georgiev, S. O'Dell, G. Y. Chuang, R. P. Staupe, J. S. McLellan, J. Gorman, M. Pancera, M. Bonsignori, B. F. Haynes, D. R. Burton, W. C. Koff, P. D. Kwong and J. R. Mascola (2012). "A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies." J Virol 86(15): 8319-8323.

               

Dosenovic, P., M. Soldemo, J. L. Scholz, S. O'Dell, E. K. Grasset, N. Pelletier, M. C. Karlsson, J. R. Mascola, R. T. Wyatt, M. P. Cancro and G. B. Karlsson Hedestam (2012). "BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses." J Immunol 188(12): 6018-6026.

                Neutralizing Abs provide the protective effect of the majority of existing human vaccines. For a prophylactic

Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L. M. Walker, X. Wu, M. S. Seaman, T. Wrin, P. D. Kwong, R. T. Wyatt, J. R. Mascola, P. Poignard and D. R. Burton (2012). "PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4." J Virol 86(8): 4394-4403.

               

Feng, Y., K. McKee, K. Tran, S. O'Dell, S. D. Schmidt, A. Phogat, M. N. Forsell, G. B. Karlsson Hedestam, J. R. Mascola and R. T. Wyatt (2012). "Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site." J Biol Chem 287(8): 5673-5686.

                .

Finzi, A., B. Pacheco, S. H. Xiang, M. Pancera, A. Herschhorn, L. Wang, X. Zeng, A. Desormeaux, P. D. Kwong and J. Sodroski (2012). "Lineage-specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding." J Virol 86(17): 8974-8986.

Fukazawa, Y., H. Park, M. J. Cameron, F. Lefebvre, R. Lum, N. Coombes, E. Mahyari, S. I. Hagen, J. Y. Bae, M. D. Reyes, 3rd, T. Swanson, A. W. Legasse, A. Sylwester, S. G. Hansen, A. T. Smith, P. Stafova, R. Shoemaker, Y. Li, K. Oswald, M. K. Axthelm, A. McDermott, G. Ferrari, D. C. Montefiori, P. T. Edlefsen, M. Piatak, Jr., J. D. Lifson, R. P. Sekaly and L. J. Picker (2012). "Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines." Nat Med 18(11): 1673-1681.

               

               

Graham, S. M., S. E. Holte, J. A. Dragavon, K. M. Ramko, K. N. Mandaliya, R. S. McClelland, N. M. Peshu, E. J. Sanders, J. N. Krieger and R. W. Coombs (2012). "HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy." PLoS ONE 7(8): e43086.

               

Guenaga, J. and R. T. Wyatt (2012). "Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function." PLoS Pathog 8(7): e1002806.

               

Hassan, A. S., K. L. Fielding, N. M. Thuo, H. M. Nabwera, E. J. Sanders and J. A. Berkley (2012). "Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study." Trop Med Int Health 17(1): 82-93.

               

.

Hu, L., W. Song, I. Brill, J. Mulenga, S. Allen, E. Hunter, S. Shrestha, J. Tang and R. A. Kaslow (2012). "Genetic variations and heterosexual HIV-1 infection: analysis of clustered genes encoding CC-motif chemokine ligands." Genes Immun 13(2): 202-205.

               

Huang, J., G. Ofek, L. Laub, M. K. Louder, N. A. Doria-Rose, N. S. Longo, H. Imamichi, R. T. Bailer, B. Chakrabarti, S. K. Sharma, S. M. Alam, T. Wang, Y. Yang, B. Zhang, S. A. Migueles, R. Wyatt, B. F. Haynes, P. D. Kwong, J. R. Mascola and M. Connors (2012). "Broad and potent neutralization of HIV-1 by a gp41-specific human antibody." Nature 491(7424): 406-412.

               

Hue, S., A. S. Hassan, H. Nabwera, E. J. Sanders, D. Pillay, J. A. Berkley and P. A. Cane (2012). "HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination." AIDS Res Hum Retroviruses 28(2): 220-224.

               

Julien, J. P., P. S. Lee and I. A. Wilson (2012). "Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA." Immunol Rev 250(1): 180-198.

               

Jurgens, C. K., K. R. Young, V. J. Madden, P. R. Johnson and R. E. Johnston (2012). "A novel self-replicating chimeric lentivirus-like particle." J Virol 86(1): 246-261.

               

Keefer, M. C., J. Gilmour, P. Hayes, D. Gill, J. Kopycinski, H. Cheeseman, M. Cashin-Cox, M. Naarding, L. Clark, N. Fernandez, C. A. Bunce, C. M. Hay, S. Welsh, W. Komaroff, L. Hachaambwa, T. Tarragona-Fiol, E. Sayeed, D. Zachariah, J. Ackland, K. Loughran, B. Barin, E. Cormier, J. H. Cox, P. Fast and J. L. Excler (2012). "A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults." PLoS ONE 7(8): e41936.

               

Ketas, T. J., S. Holuigue, K. Matthews, J. P. Moore and P. J. Klasse (2012). "Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors." Virology 422(1): 22-36.

Kilembe, W., M. Keeling, E. Karita, S. Lakhi, P. Chetty, M. A. Price, H. Makkan, M. Latka, M. Likoti, K. Ilukui, M. Hurlston, S. Allen, G. Stevens and E. Hunter (2012). "Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection." PLoS ONE 7(6): e37154.

               

Klasse, P. J., R. W. Sanders, A. Cerutti and J. P. Moore (2012). "How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?" AIDS Res Hum Retroviruses 28(1): 1-15.

               

Koff, W. C. (2012). "HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem." Vaccine 30(29): 4310-4315.

               

Kopycinski, J., H. Cheeseman, A. Ashraf, D. Gill, P. Hayes, D. Hannaman, J. Gilmour, J. H. Cox and S. Vasan (2012). "A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the alpha4beta7-binding V2 loop of HIV gp120 in healthy volunteers." Clin Vaccine Immunol 19(9): 1557-1559.

               

Kwon, Y. D., A. Finzi, X. Wu, C. Dogo-Isonagie, L. K. Lee, L. R. Moore, S. D. Schmidt, J. Stuckey, Y. Yang, T. Zhou, J. Zhu, D. A. Vicic, A. K. Debnath, L. Shapiro, C. A. Bewley, J. R. Mascola, J. G. Sodroski and P. D. Kwong (2012). "Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops." Proc Natl Acad Sci U S A 109(15): 5663-5668.

               

Li, Y., S. O'Dell, R. Wilson, X. Wu, S. D. Schmidt, C. M. Hogerkorp, M. K. Louder, N. S. Longo, C. Poulsen, J. Guenaga, B. K. Chakrabarti, N. Doria-Rose, M. Roederer, M. Connors, J. R. Mascola and R. T. Wyatt (2012). "HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins." J Virol 86(20): 11231-11241.

               

MacPherson, E., J. Sadalaki, M. Njoloma, V. Nyongopa, L. Nkhwazi, V. Mwapasa, D. Lalloo, N. Desmond, J. Seeley and S. Theobald (2012). "Transactional sex and HIV: understanding the gendered structural drivers of HIV in fishing communities in Southern Malawi." J Int AIDS Soc 15(Suppl 1): 1 - 9.

               

Mao, Y., L. Wang, C. Gu, A. Herschhorn, S. H. Xiang, H. Haim, X. Yang and J. Sodroski (2012). "Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer." Nat Struct Mol Biol 19(9): 893-899.

               

Moldt, B., E. G. Rakasz, N. Schultz, P. Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard and D. R. Burton (2012). "Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo." Proc Natl Acad Sci U S A 109(46): 18921-18925.

               

Moldt, B., M. Shibata-Koyama, E. G. Rakasz, N. Schultz, Y. Kanda, D. C. Dunlop, S. L. Finstad, C. Jin, G. Landucci, M. D. Alpert, A. S. Dugast, P. W. Parren, F. Nimmerjahn, D. T. Evans, G. Alter, D. N. Forthal, J. E. Schmitz, S. Iida, P. Poignard, D. I. Watkins, A. J. Hessell and D. R. Burton (2012). "A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques." J Virol 86(11): 6189-6196.

               

Montero, M., N. Gulzar, K. A. Klaric, J. E. Donald, C. Lepik, S. Wu, S. Tsai, J. P. Julien, A. J. Hessell, S. Wang, S. Lu, D. R. Burton, E. F. Pai, W. F. Degrado and J. K. Scott (2012). "Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane." J Virol 86(6): 2930-2941.

               

Mouquet, H., L. Scharf, Z. Euler, Y. Liu, C. Eden, J. F. Scheid, A. Halper-Stromberg, P. N. Gnanapragasam, D. I. Spencer, M. S. Seaman, H. Schuitemaker, T. Feizi, M. C. Nussenzweig and P. J. Bjorkman (2012). "Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies." Proc Natl Acad Sci U S A 109(47): E3268-3277.

               

Mouquet, H., M. Warncke, J. F. Scheid, M. S. Seaman and M. C. Nussenzweig (2012). "Enhanced HIV-1 neutralization by antibody heteroligation." Proc Natl Acad Sci U S A 109(3): 875-880.

               

Mutua, G., E. Sanders, P. Mugo, O. Anzala, J. E. Haberer, D. Bangsberg, B. Barin, J. F. Rooney, D. Mark, P. Chetty, P. Fast and F. H. Priddy (2012). "Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers." PLoS ONE 7(4): e33103.

               

Ngongo, P. B., F. Priddy, H. Park, J. Becker, B. Bender, P. Fast, O. Anzala, G. Mutua, E. Ruzagira, A. Kamali, E. Karita, P. Mugo, E. Chomba, L. G. Bekker, S. Roux, A. Nanvubya and T. Mebrahtu (2012). "Developing standards of care for HIV prevention research in developing countries -- a case study of 10 research centers in Eastern and Southern Africa." AIDS Care 24(10): 1277-1289.

               

Nitayaphan, S., V. Ngauy, R. O'Connell and J. L. Excler (2012). "HIV epidemic in Asia: optimizing and expanding vaccine development." Expert Rev Vaccines 11(7): 805-819.

               

Nunan, F., J. Luomba, C. Lwenya, E. Yongo, K. Odongkara and B. Ntambi (2012). "Finding space for participation: fisherfolk mobility and co-management of Lake Victoria fisheries." Environ Manage 50: 204 - 216.

               

Olivier, A. J., L. J. Liebenberg, D. Coetzee, A. L. Williamson, J. A. Passmore and W. A. Burgers (2012). "Isolation and characterization of T cells from semen." J Immunol Methods 375(1-2): 223-231.

               

Ota, T., C. Doyle-Cooper, A. B. Cooper, M. Huber, E. Falkowska, K. J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, J. Lifson, X. Wu, J. R. Mascola, P. Poignard, J. M. Binley, B. K. Chakrabarti, W. R. Schief, R. T. Wyatt, D. R. Burton and D. Nemazee (2012). "Anti-HIV B Cell lines as candidate vaccine biosensors." J Immunol 189(10): 4816-4824.

                .

Pantazis, N., C. Morrison, P. N. Amornkul, C. Lewden, R. A. Salata, A. Minga, T. Chipato, H. Jaffe, S. Lakhi, E. Karita, K. Porter, L. Meyer, G. Touloumi, C. C. i. EuroCoord and A. P.-C. S. Group (2012). "Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa." PLoS ONE 7(3): e32369.

               

Postler, T. S., J. M. Martinez-Navio, E. Yuste and R. C. Desrosiers (2012). "Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein." J Virol 86(2): 1145-1157.

               

Price, M. A., W. Rida, M. Mwangome, G. Mutua, K. Middelkoop, S. Roux, H. S. Okuku, L. G. Bekker, O. Anzala, E. Ngugi, G. Stevens, P. Chetty, P. N. Amornkul and E. J. Sanders (2012). "Identifying at-risk populations in Kenya and South Africa: HIV incidence in cohorts of men who report sex with men, sex workers, and youth." J Acquir Immune Defic Syndr 59(2): 185-193.

               

Ratto-Kim, S., J. R. Currier, J. H. Cox, J. L. Excler, A. Valencia-Micolta, D. Thelian, V. Lo, E. Sayeed, V. R. Polonis, P. L. Earl, B. Moss, M. L. Robb, N. L. Michael, J. H. Kim and M. A. Marovich (2012). "Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens." PLoS ONE 7(9): e45840.

               

Reynolds, M. R., A. M. Weiler, S. M. Piaskowski, M. Piatak, Jr., H. T. Robertson, D. B. Allison, A. J. Bett, D. R. Casimiro, J. W. Shiver, N. A. Wilson, J. D. Lifson, W. C. Koff and D. I. Watkins (2012). "A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge." Vaccine 30(30): 4465-4475.

               

Ringe, R., S. Phogat and J. Bhattacharya (2012). "Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies." Virology 426(1): 34-41.

               

Schmidt, C., C. Smith, B. Barin, A. Bakhtyari, P. A. Bart, L. G. Bekker, E. Chomba, N. Clumeck, D. Ho, A. Hoosen, W. Jaoko, P. Kaleebu, E. Karita, M. C. Keefer, J. van Lunzen, A. McMichael, S. Mehendale, B. Peters, V. D. Ramanathan, A. Robinson, J. Rockstroh, E. Vardas, E. Vets, J. Weber, B. S. Graham, S. Than, J. L. Excler, S. Kochhar, M. Ho, A. Heald and P. E. Fast (2012). "Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events." Hum Vaccin Immunother 8(5): 630-638.

               

Seeley, J., J. Nakiyingi-Miiro, A. Kamali, J. Mpendo, G. Asiki, A. Abaasa, B. De, L. Nielsen and P. Kaleebu (2012). "High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda." Sex Transm Dis 39: 433 - 439.

               

Sullivan, P. S., A. Carballo-Diéguez, T. Coates, S. M. Goodreau, I. McGowan, E. J. Sanders, A. Smith, P. Goswami and J. Sanchez (2012). "Successes and challenges of HIV prevention in men who have sex with men." The Lancet 380(9839): 388-399.

               

Sullivan, P. S., U. Fideli, K. M. Wall, E. Chomba, C. Vwalika, W. Kilembe, A. Tichacek, N. Luisi, J. Mulenga, E. Hunter, D. Boeras and S. Allen (2012). "Prevalence of seroconversion symptoms and relationship to set-point viral load: findings from a subtype C epidemic, 1995-2009." Aids 26(2): 175-184.

               

Sundling, C., Y. Li, N. Huynh, C. Poulsen, R. Wilson, S. O'Dell, Y. Feng, J. R. Mascola, R. T. Wyatt and G. B. Karlsson Hedestam (2012). "High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site." Sci Transl Med 4(142): 142ra196.

               

Thigpen, M., P. Kebaabetswe, L. Paxton, D. Smith, C. Rose, T. Segolodi, F. Henderson, S. Pathak, F. Soud, K. Chillag, R. Mutanhaurwa, L. Chirwa, M. Kasonde, D. Abebe, E. Buliva, R. Gvetadze, S. Johnson, T. Sukalac, V. Thomas, C. Hart, J. Johnson, C. Malotte, C. Hendrix and J. Brooks (2012). "Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana." N Engl J Med 367: 423 - 434.

               

               

Wall, K., E. Karita, A. Nizam, B. Bekan, G. Sardar, D. Casanova, D. Joseph Davey, F. De Clercq, E. Kestelyn, R. Bayingana, A. Tichacek and S. Allen (2012). "Influence network effectiveness in promoting couples' HIV voluntary counseling and testing in Kigali, Rwanda." AIDS 26(2): 217-227.

               

Wall, K. M., W. Kilembe, A. Nizam, C. Vwalika, M. Kautzman, E. Chomba, A. Tichacek, G. Sardar, D. Casanova, F. Henderson, J. Mulenga, D. Kleinbaum and S. Allen (2012). "Promotion of couples' voluntary HIV counselling and testing in Lusaka, Zambia by influence network leaders and agents." BMJ Open 2(5).